United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

Key Points

• United Therapeutics CEO Martine Rothblatt sold 4,000 shares of the company at an average price of $440.43, resulting in a significant 96.85% decrease in her ownership position.
• The company's stock is currently trading at $432.19, down 0.3%, and has a one-year range between $266.98 and $459.48.
• Despite reporting a miss on EPS estimates for the last quarter, United Therapeutics showed an 11.7% increase in revenue year-over-year.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $440.43, for a total value of $1,761,720.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company's stock, valued at $57,255.90. This represents a 96.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

United Therapeutics Stock Down 0.3%

Shares of UTHR stock traded down $1.42 during mid-day trading on Wednesday, reaching $432.19. The stock had a trading volume of 658,832 shares, compared to its average volume of 595,331. The firm's 50 day simple moving average is $377.79 and its 200 day simple moving average is $325.47. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $459.48. The firm has a market cap of $19.50 billion, a PE ratio of 16.87, a P/E/G ratio of 4.80 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the prior year, the business posted $5.85 EPS. United Therapeutics's revenue was up 11.7% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent research reports. Morgan Stanley increased their target price on United Therapeutics from $328.00 to $435.00 and gave the stock an "equal weight" rating in a report on Friday, October 10th. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Weiss Ratings reissued a "hold (c+)" rating on shares of United Therapeutics in a report on Wednesday, October 8th. HC Wainwright increased their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a report on Friday, September 5th. Finally, UBS Group increased their target price on United Therapeutics from $560.00 to $580.00 and gave the stock a "buy" rating in a report on Monday, September 29th. Ten investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $457.21.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC increased its holdings in United Therapeutics by 76.9% during the 3rd quarter. CWM LLC now owns 9,189 shares of the biotechnology company's stock valued at $3,852,000 after purchasing an additional 3,995 shares in the last quarter. Inspire Investing LLC boosted its position in United Therapeutics by 14.4% in the 3rd quarter. Inspire Investing LLC now owns 7,325 shares of the biotechnology company's stock valued at $3,071,000 after buying an additional 921 shares during the last quarter. Brookstone Capital Management increased its stake in shares of United Therapeutics by 7.1% in the 3rd quarter. Brookstone Capital Management now owns 5,280 shares of the biotechnology company's stock valued at $2,213,000 after buying an additional 349 shares during the period. IFM Investors Pty Ltd raised its position in shares of United Therapeutics by 1.5% during the third quarter. IFM Investors Pty Ltd now owns 8,647 shares of the biotechnology company's stock worth $3,741,000 after acquiring an additional 128 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in shares of United Therapeutics by 149.3% during the third quarter. Farther Finance Advisors LLC now owns 177 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 106 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.